Valneva (VALN) Competitors

ImmunityBio (NASDAQ:IBRX) and Valneva (NASDAQ:VALN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, community ranking, earnings, valuation and profitability.

Is IBRX or VALN more profitable?

Valneva has a net margin of -4.35% compared to ImmunityBio's net margin of -8,016.83%. ImmunityBio's return on equity of 0.00% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-8,016.83%	N/A	-110.02%
Valneva	-4.35%	-3.93%	-1.42%

Does the MarketBeat Community prefer IBRX or VALN?

Valneva received 20 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 66.13% of users gave Valneva an outperform vote while only 50.00% of users gave ImmunityBio an outperform vote.

Company	Underperform	Outperform
ImmunityBio	Outperform Votes 21 50.00%	Underperform Votes 21 50.00%
Valneva	Outperform Votes 41 66.13%	Underperform Votes 21 33.87%

Does the media prefer IBRX or VALN?

In the previous week, Valneva had 2 more articles in the media than ImmunityBio. MarketBeat recorded 11 mentions for Valneva and 9 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.76 beat Valneva's score of 0.53 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Valneva	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate IBRX or VALN?

ImmunityBio presently has a consensus price target of $12.19, suggesting a potential upside of 398.47%. Valneva has a consensus price target of $16.00, suggesting a potential upside of 151.53%. Given ImmunityBio's higher probable upside, analysts clearly believe ImmunityBio is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Valneva	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher valuation and earnings, IBRX or VALN?

Valneva has higher revenue and earnings than ImmunityBio. Valneva is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$14.75M	141.52	-$583.20M	-$0.63	-3.88
Valneva	$169.58M	3.14	-$109.78M	-$0.17	-37.42

Which has more volatility and risk, IBRX or VALN?

ImmunityBio has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Valneva has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500.

Do institutionals & insiders have more ownership in IBRX or VALN?

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 83.4% of ImmunityBio shares are held by company insiders. Comparatively, 14.9% of Valneva shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Valneva beats ImmunityBio on 10 of the 18 factors compared between the two stocks.